Cancer Segment to Lead US and Europe Cell and Gene Therapy Manufacturing Services Market During 2022–2030

According to our new research study on “US and Europe Cell and Gene Therapy Manufacturing Services Market Forecast to 2030 – Country Analysis – by Type, Indication, Application, and End User,” the US and Europe cell and gene therapy manufacturing services market size is expected to grow from US$ 4,773.5 million in 2022 to US$ 16,869.1 million by 2030; it is estimated to record a CAGR of 17.1% from 2022–2030. 

Factors driving the US and Europe cell and gene therapy manufacturing services market growth are increase in number of approvals of cell and gene therapies and increasing popularity of outsourcing cell and gene therapy manufacturing.

The US and Europe cell and gene therapy manufacturing services market, by indication, is segmented into cancer, orthopedics, and others. The cancer segment held the largest US and Europe cell and gene therapy manufacturing services market share in 2022 and is anticipated to register the highest CAGR during the forecast period. The broad field of cell and gene therapy promises many innovative treatments that have the potential to prevent deaths from cancer. According to the April 2022 newsletter by Alliance for Cancer Gene Therapy, Inc., 6 CAR T-cell therapies have been approved by the US Food and Drug Administration (FDA) for the treatment of myeloma, leukemia, and lymphoma. In December 2022, the FDA approved Adstiladrin, a non-replicating adenoviral vector-based gene therapy, for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. In 2022, FDA approved Kimmtrak, a T-cell receptor therapy for a rare type of melanoma in the eye—uveal melanoma. As there is an increase in the number of FDA approvals of cell and gene therapy for the treatment of cancer, the production of these therapies has increased in the last several years. Thus, a large number of CDMOs are focusing on providing manufacturing services for cancer cell and gene therapies. Such factors promote the US and Europe cell and gene therapy manufacturing services market growth for the cancer segment during the forecast period.

The US held the largest share of the US and Europe cell and gene therapy manufacturing services market. The US Food and Drug Administration (USFDA) has approved only 7 CGT drugs, with the pipeline of new products reaching ~1,200 experimental therapies. Half of these are in Phase 2 clinical trials, with estimates of annual sales growth accounting for 15% for cell therapies and ~30% for gene therapies, as per the estimates of the Chemical & Engineering News report 2023.

Many manufacturers approach contract development manufacturing organizations (CDMOs) such as Labcorp, Lonza, and Catalent to overcome the barriers associated with the production and commercialization of their cell and gene therapy products. Lonza has invested ~US$ 9.2 million to strengthen its cell and gene therapy manufacturing capabilities and support. Such initiatives by CDMOs are contributing to the cell and gene therapy manufacturing services market growth in the country.

Thermo Fisher Scientific Inc, Merck KGaA, Charles River Laboratories International Inc, Lonza Group AG, WuXi AppTec Co Ltd, Catalent Inc, Takara Bio Inc, Nikon Corp, FUJIFILM Holdings Corp, National Resilience Inc, and Oxford BioMedica Plc are among the leading companies operating in the US and Europe cell and gene therapy manufacturing services market.

Based on type, the US and Europe cell and gene therapy manufacturing services market is segmented into cell therapy and gene therapy. In terms of indication, the US and Europe cell and gene therapy manufacturing services market is segmented into cancer, orthopaedics, and others. By application, the US and Europe cell and gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing. In terms of end user, the US and Europe cell and gene therapy manufacturing services market is segmented into pharmaceutical and biotechnology companies and contract research organization (CROs). By country, the US and Europe cell and gene therapy manufacturing services market is segmented into US and Europe (Germany, UK, France, Italy, Spain, and Rest of Europe).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com